Investor Relations Press Releases 13 Nov 24 GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 07 Nov 24 GENFIT Reports Third Quarter 2024 Financial Information 23 Sep 24 GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval View All
23 Sep 24 GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
